SPERO THERAPEUTICS INC's ticker is SPRO and the CUSIP is 84833T103. A total of 80 filers reported holding SPERO THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.90 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $144,830 | -73.3% | 119,694 | -68.0% | 0.00% | – |
| Q2 2023 | $542,082 | +75504.2% | 373,850 | -24.4% | 0.00% | – |
| Q1 2023 | $717 | -52.7% | 494,541 | -43.6% | 0.00% | -100.0% |
| Q4 2022 | $1,516 | -99.9% | 876,398 | +27.3% | 0.00% | 0.0% |
| Q3 2022 | $1,377,000 | +491.0% | 688,396 | +118.8% | 0.00% | – |
| Q2 2022 | $233,000 | -56.3% | 314,643 | +413.6% | 0.00% | – |
| Q1 2022 | $533,000 | +186.6% | 61,261 | +384.9% | 0.00% | – |
| Q1 2021 | $186,000 | -83.5% | 12,635 | -78.2% | 0.00% | -100.0% |
| Q4 2020 | $1,126,000 | -22.7% | 58,062 | -55.5% | 0.00% | -50.0% |
| Q3 2020 | $1,457,000 | +199.2% | 130,574 | +262.8% | 0.00% | +100.0% |
| Q2 2020 | $487,000 | +327.2% | 35,993 | +156.1% | 0.00% | – |
| Q1 2020 | $114,000 | -6.6% | 14,055 | +10.8% | 0.00% | – |
| Q4 2019 | $122,000 | -25.2% | 12,682 | +11.1% | 0.00% | – |
| Q1 2018 | $163,000 | – | 11,415 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Atlas Venture Associates IX, LLC | 1,353,303 | $1,637,497 | 13.93% |
| Anson Funds Management LP | 4,159,572 | $5,033,082 | 1.01% |
| OUP Management Co., LLC | 249,070 | $301,375 | 0.68% |
| Atlas Venture Life Science Advisors, LLC | 1,013,438 | $1,226,260 | 0.19% |
| Murchinson Ltd. | 862,700 | $1,043,867 | 0.13% |
| Alphabet Inc. | 889,979 | $1,076,874 | 0.07% |
| AWM Investment Company, Inc. | 333,400 | $403,414 | 0.06% |
| DAFNA Capital Management LLC | 125,000 | $151,250 | 0.05% |
| Novo Holdings A/S | 468,902 | $567,371 | 0.04% |
| XTX Topco Ltd | 58,368 | $70,625 | 0.01% |